The basic principle is to resist the immunosuppressive effect of the tumor microenvironment by targeting the immune checkpoint receptors—CTLA4, PD1 and their ligands (PDL1, PDL2), so as to remove the immune suppression and enhance the immune function to play an anti-tumor role. This evidence concerns the gene CTLA4 and neoplasm.